Winfield Associates’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Winfield Associates’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-500	Closed	-$20K	–	767
2016 Q1	$20K	Hold	500	–	–	0.01%	237
2015 Q4	$26K	Sell	500 -1,000	-67%	-$51K	0.02%	201
2015 Q3	$70K	Buy	+1,500	New	+$90.4K	0.05%	140

Other funds holding XPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

KHLMVGHM

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $2.44B AUM 24.95% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

Winfield Associates's XPH Position: Q2 2016 in Review

Winfield Associates sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2016, closing a stake of 500 shares — an estimated $20K sold.

Winfield Associates first reported a position in XPH in Q3 2015 and held it in 3 quarters. The position peaked at $70K in Q3 2015. 60 funds tracked by Wall St. Rank hold XPH as of Q2 2016.

Winfield Associates reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2016 after selling out during the quarter.
Winfield Associates sold 500 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2016, an estimated $20K.
Winfield Associates first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q3 2015 and held it in 3 quarters.
Winfield Associates's State Street SPDR S&P Pharmaceuticals ETF position peaked at $70K in Q3 2015.
60 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2016.

Based on Winfield Associates's 13F filing for Q2 2016, filed 15 Aug 2016.